Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU

PHASE3CompletedINTERVENTIONAL
Enrollment

613

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Formoterol Turbuhaler® 4.5mg

4.5 mg inhaled twice daily

DRUG

Formoterol Turbuhaler® 9 mg

9 mg inhaled twice daily

DRUG

Turbuhaler® placebo

placebo inhaled twice daily

Trial Locations (47)

Unknown

Research Site, Gabrovo

Research Site, Lovech

Research Site, Pleven

Research Site, Rousse

Research Site, Sofia

Research Site, Stara Zagora

Research Site, Troyan Municipality

Research Site, Varna

Research Site, Nagoya

Research Site, Seto

Research Site, Noda

Research Site, Touon

Research Site, Yanagawa

Research Site, Ōta

Research Site, Ōwa

Research Site, Hiroshima

Research Site, Asahikawa

Research Site, Chitose

Research Site, Obihiro

Research Site, Sapporo

Research Site, Tomakomai

Research Site, Yabu

Research Site, Naka-gun

Research Site, Morioka

Research Site, Kagoshima

Research Site, Kawasaki

Research Site, Kochi

Research Site, Kyoto

Research Site, Sendai

Research Site, Katano

Research Site, Kishiwada

Research Site, Osaka

Research Site, Takatsuiki

Research Site, Chiyoda City

Research Site, Wakayama

Research Site, Ube

Research Site, Deva

Research Site, Bucharest

Research Site, Constanța

Research Site, Iași

Research Site, Kazan'

Research Site, Moscow

Research Site, Saint Petersburg

Research Site, Dnipropetrovsk

Research Site, Donetsk

Research Site, Kharkiv

Research Site, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY